These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35005601)

  • 1. Establishment of a pseudovirus neutralization assay based on SARS-CoV-2 S protein incorporated into lentiviral particles.
    Wang S; Liu L; Wang C; Wang Z; Duan X; Chen G; Zhou H; Shao H
    Biosaf Health; 2022 Feb; 4(1):38-44. PubMed ID: 35005601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2.
    Hu J; Gao Q; He C; Huang A; Tang N; Wang K
    Genes Dis; 2020 Dec; 7(4):551-557. PubMed ID: 32837985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.
    Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.
    Zhao G; Du L; Ma C; Li Y; Li L; Poon VK; Wang L; Yu F; Zheng BJ; Jiang S; Zhou Y
    Virol J; 2013 Aug; 10():266. PubMed ID: 23978242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays.
    Yu J; Li Z; He X; Gebre MS; Bondzie EA; Wan H; Jacob-Dolan C; Martinez DR; Nkolola JP; Baric RS; Barouch DH
    J Virol; 2021 May; 95(11):. PubMed ID: 33727331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays.
    Manu AA; Owusu IA; Oyawoye FO; Languon S; Barikisu IA; Tawiah-Eshun S; Quaye O; Donkor KJ; Paemka L; Amegatcher GA; Denyoh PMD; Oduro-Mensah D; Awandare GA; Quashie PK
    Heliyon; 2024 May; 10(10):e31392. PubMed ID: 38826759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2.
    Neerukonda SN; Vassell R; Herrup R; Liu S; Wang T; Takeda K; Yang Y; Lin TL; Wang W; Weiss CD
    PLoS One; 2021; 16(3):e0248348. PubMed ID: 33690649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a SARS-CoV-2 neutralization assay based on a pseudotyped virus using a HIV system.
    Liang Z; Tong J; Wu X; Liu S; Wu J; Yu Y; Zhang L; Zhao C; Lu Q; Nie J; Huang W; Wang Y
    MedComm (2020); 2024 Apr; 5(4):e517. PubMed ID: 38525106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.
    Mou H; Quinlan BD; Peng H; Liu G; Guo Y; Peng S; Zhang L; Davis-Gardner ME; Gardner MR; Crynen G; DeVaux LB; Voo ZX; Bailey CC; Alpert MD; Rader C; Gack MU; Choe H; Farzan M
    PLoS Pathog; 2021 Apr; 17(4):e1009501. PubMed ID: 33836016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay.
    Donofrio G; Franceschi V; Macchi F; Russo L; Rocci A; Marchica V; Costa F; Giuliani N; Ferrari C; Missale G
    Vaccines (Basel); 2021 Apr; 9(4):. PubMed ID: 33920999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2-Based High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation.
    Cai Z; Kalkeri R; Zhu M; Cloney-Clark S; Haner B; Wang M; Osman B; Dent D; Feng SL; Longacre Z; Glenn G; Plested JS
    Microorganisms; 2024 Feb; 12(3):. PubMed ID: 38543552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles.
    Wu C; Xu Q; Wang H; Tu B; Zeng J; Zhao P; Shi M; Qiu H; Huang Y
    Acta Pharm Sin B; 2022 Mar; 12(3):1523-1533. PubMed ID: 34522576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD.
    Septisetyani EP; Prasetyaningrum PW; Anam K; Santoso A
    Immune Netw; 2021 Dec; 21(6):e39. PubMed ID: 35036026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials.
    Sholukh AM; Fiore-Gartland A; Ford ES; Hou Y; Tse LV; Lempp FA; Kaiser H; Saint Germain R; Bossard E; Kee JJ; Diem K; Stuart AB; Rupert PB; Brock C; Buerger M; Doll MK; Randhawa AK; Stamatatos L; Strong RK; McLaughlin C; Jerome KR; Baric RS; Montefiori D; Corey L
    medRxiv; 2020 Dec; ():. PubMed ID: 33330875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of SARS-CoV-2 pseudovirus invasion by ACE2 protecting and Spike neutralizing peptides: An alternative approach to COVID19 prevention and therapy.
    Chen J; Li S; Lei Z; Tang Q; Mo L; Zhao X; Xie F; Zi D; Tan J
    Int J Biol Sci; 2021; 17(11):2957-2969. PubMed ID: 34345219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.
    Zeng X; Li L; Lin J; Li X; Liu B; Kong Y; Zeng S; Du J; Xiao H; Zhang T; Zhang S; Liu J
    Antib Ther; 2020 Apr; 3(2):95-100. PubMed ID: 33912790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interactions of ZDHHC5/GOLGA7 with SARS-CoV-2 spike (S) protein and their effects on S protein's subcellular localization, palmitoylation and pseudovirus entry.
    Zeng XT; Yu XX; Cheng W
    Virol J; 2021 Dec; 18(1):257. PubMed ID: 34961524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of Efficient Adjuvants for the RBD-Based Subunit Vaccine of SARS-CoV-2.
    Shi J; Zhao Y; Peng M; Zhu S; Wu Y; Ji R; Shen C
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.